Adaptive Biotechnologies (ADPT) Q2 2024: MRD Revenue Up 36% as Pharma Bookings and Cost Discipline Reshape Trajectory
Adaptive Biotechnologies delivered a pivotal quarter, pairing robust MRD growth with aggressive cost cuts and improved sequencing margin. Pharma bookings and primary endpoint adoption signal durable tailwinds, while ongoing margin initiatives and ASP improvements strengthen the outlook. Execution on EMR integration and targeted investments in market access and reimbursement underpin confidence in long-term leverage and break-even targets.
Summary
- MRD Momentum Accelerates: Primary endpoint adoption and pharma study bookings set up multi-year tailwinds.
- Margin and Cash Burn Improvement: Sequencing margin and OpEx progress outpace expectations, strengthening financial flexibility.
- Strategic Investments Focused: EMR integration and market access initiatives drive sustainable growth and ASP expansion.
Business Overview
Adaptive Biotechnologies is a commercial-stage biotech specializing in immune-driven diagnostics and therapeutics. The company’s core business is minimal residual disease (MRD) testing through its FDA-cleared ClonoSeq assay, which detects and monitors blood cancers. Revenue is generated via clinical testing for oncologists and pharma partnerships supporting drug development. Its secondary segment, immune medicine, leverages TCR (T-cell receptor) sequencing for therapeutic discovery, mainly in oncology and autoimmunity, with R&D and pharma service revenue streams.
Performance Analysis
Q2 2024 marked a turning point for Adaptive, with MRD revenue surging 36% year-over-year, supported by record clinical test volumes and continued pharma momentum. Clinical MRD testing saw double-digit volume growth across all marketed indications, with multiple myeloma remaining the largest contributor. The pharma MRD business benefitted from a $3 million milestone and a notable increase in studies adopting MRD as a primary endpoint, a shift catalyzed by recent regulatory tailwinds. Meanwhile, immune medicine revenue declined as expected due to lower Genentech milestone recognition, partially offset by growth in pharma services.
Cost discipline was a standout, with total operating spend (excluding one-time items) down 15% YoY and 8% sequentially. Sequencing gross margin improved by 5 percentage points quarter-over-quarter, reaching 50%, attributed to lab efficiency gains and higher throughput. Cash burn reduction was significant, down 32% in the first half versus last year, and annual guidance was lowered further. Adjusted EBITDA loss narrowed sharply, especially in the MRD segment, reflecting both revenue growth and spending controls.
- Clinical Volume Expansion: Over 18,500 MRD tests delivered, with blood-based testing now 40% of total volume.
- Pharma Bookings Surge: Two new studies and three in advanced discussions for primary endpoint use, with milestone economics expected to improve in 2025.
- Sequencing Margin Leverage: Efficiency initiatives and volume growth drove 7 percentage point YoY improvement in sequencing margin.
Adaptive’s results reflect a business scaling rapidly in its core MRD franchise, while operational and capital discipline support a more sustainable long-term profile.
Executive Commentary
"We are laser focused on fueling growth on the top line, reducing spend, and managing our capital. And this is exactly what we achieved this quarter ... MRD revenue grew 36% versus prior year, and 8% versus prior quarter, with growth coming from both clinical and pharma. Total operating spend, less one-time costs, had a significant decline of 15% versus prior year and 8% sequentially."
Chad Robbins, CEO and Co-founder
"Sequencing margin, which excludes the MRD milestones and Genentech amortization, was 50% for the quarter, an increase of 7 percentage points versus prior year and 5 percentage points sequentially. The sequencing margin increase was mainly attributed to lower overhead costs from improvements in the production lab driving lower costs per sample."
Kyle Piskel, Chief Financial Officer
Strategic Positioning
1. MRD Platform Scaling and Pharma Adoption
ClonoSeq’s position as the only FDA-cleared MRD assay is being reinforced as pharma partners increasingly adopt MRD as a primary endpoint in new studies. The recent ODAC (Oncologic Drugs Advisory Committee) vote in favor of MRD as a surrogate endpoint for accelerated drug approval in multiple myeloma has accelerated bookings and is already influencing other lymphoid malignancies. Adaptive’s leadership expects this to be a durable multi-year growth driver, with milestone and sequencing revenues benefiting as more trials use MRD endpoints.
2. ASP and Reimbursement Levers
Adaptive is executing a multi-pronged strategy to lift average selling price (ASP) per test by $200 by end of 2025. This includes expanding Medicare coverage, negotiating higher rates with commercial payers, and improving collections, especially for Medicare Advantage. The preliminary CLFS (Clinical Laboratory Fee Schedule) gap fill rate provides leverage in payer negotiations, and operational changes are reducing out-of-policy claims, supporting near-term ASP gains and long-term pricing power.
3. Margin Expansion Through Operational Efficiency
Sequencing margin improvements are being driven by volume growth and lab efficiency, with further upside anticipated from the NovaSeq platform launch in late 2025. Management targets 70% sequencing margin over a three- to five-year horizon, with NovaSeq expected to deliver 5 to 8 percentage points of margin improvement once fully implemented. Cost reductions in R&D and G&A, coupled with targeted investment in market access, underpin a path to break-even in the back half of 2025.
4. EMR Integration as a Growth Catalyst
Electronic medical record (EMR) integration is emerging as a competitive moat and adoption driver. Six accounts are now live in Epic, with 13 more in progress and broader Flatiron Health integration planned for Q4. Early data show double-digit increases in test adoption and ordering providers, with operational benefits in billing and claims accuracy. Larger accounts are expected to come online by year-end, supporting further clinical volume growth in 2025.
5. Immune Medicine Focused Investment
Investment in immune medicine is now highly targeted, with R&D focused on differentiated TCR-based therapeutics in oncology and autoimmunity. Recent progress includes target discovery in type 1 diabetes and successful antibody campaigns in multiple sclerosis and T1D. Spending discipline in this segment is being maintained, with most capital allocated to the MRD franchise.
Key Considerations
This quarter marks a shift from pure revenue growth to sustainable operating leverage, with Adaptive’s execution aligning with its long-term vision of dominating MRD testing and monetizing immune medicine R&D.
Key Considerations:
- Primary Endpoint Adoption Tailwind: Pharma’s rapid shift to MRD as a primary endpoint, post-ODAC, is expanding the addressable market and improving deal economics for Adaptive.
- Pricing and Reimbursement Execution: ASP gains are materializing from better coverage, contracting, and collections, with further upside as new Medicare rates become benchmarks for commercial payers.
- Operational Leverage Realization: Cost reductions are not impacting top-line growth, with sales and marketing investment held steady and further efficiency gains expected from NovaSeq and workflow optimization.
- Community Penetration Opportunity: Community oncology remains underpenetrated, representing a major growth lever as peer-to-peer education and EMR integration take hold.
- Immune Medicine Rationalization: R&D spend is being tightly managed, focusing on high-impact programs and deprioritizing less accretive initiatives like the LIMS overhaul in favor of near-term ROI projects.
Risks
Adaptive faces execution risk in sustaining MRD volume growth while expanding into new indications and maintaining payer reimbursement momentum. The pace of pharma adoption of MRD primary endpoints, while robust, is subject to regulatory and competitive shifts. Immune medicine remains a longer-term bet with uncertain timelines for monetization. Any delays in EMR integration or NovaSeq deployment could impact margin expansion. Macro-level biotech funding and shifting payer policies also pose ongoing uncertainties.
Forward Outlook
For Q3 and Q4 2024, Adaptive guided to:
- MRD revenue split 45% in Q3 and 55% in Q4, reflecting seasonality and milestone timing
- Operating spend (ex-one-time items) of $340 million to $359 million for the full year
For full-year 2024, management raised MRD revenue guidance to $140 million to $145 million, and lowered expected annual cash burn to $115 million (down from $130 million).
Management highlighted several factors that will drive results:
- Continued pharma bookings and milestone conversion
- Steady clinical test volume growth, especially in blood-based and community settings
- Ongoing cost leverage and targeted investments in market access and EMR integration
Takeaways
Adaptive’s Q2 execution confirms its pivot to a more durable, margin-expanding growth model, anchored by its leadership in MRD and a disciplined approach to capital allocation.
- Pharma and Clinical Synergy: Regulatory momentum and pharma adoption of MRD endpoints are reinforcing clinical growth and creating a robust revenue backlog for 2025 and beyond.
- Margin and Cash Burn Progress: Sequencing margin gains and OpEx reductions are translating into improved EBITDA and lower cash burn, supporting the path to break-even.
- Execution Watchpoints: Investors should monitor the pace of EMR integration, ASP realization, and pharma study conversion as leading indicators of sustained operating leverage.
Conclusion
Adaptive Biotechnologies delivered a quarter of decisive operational and strategic progress, with MRD outperformance, cost discipline, and pharma momentum all converging to de-risk the long-term growth story. Execution on reimbursement, EMR integration, and operational leverage will be key to sustaining this trajectory into 2025 and beyond.
Industry Read-Through
Adaptive’s results and commentary signal a broader inflection for the MRD and molecular diagnostics space. Pharma’s shift to MRD as a primary endpoint, supported by regulatory clarity, is likely to accelerate adoption and monetization for other MRD assay providers and related drug development platforms. Sequencing margin improvements and EMR integration are emerging as must-haves for diagnostics companies seeking scale and payer efficiency. For the broader biotech sector, Adaptive’s disciplined capital allocation and focus on operating leverage offer a template for navigating funding constraints while sustaining innovation.